These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8827856)
1. Age of illness onset and schizophrenic symptomatology during an inpatient washout period. Sharma RP; Dowd SM; Davis JM; Janicak PG Schizophr Res; 1996 Jul; 20(3):295-300. PubMed ID: 8827856 [TBL] [Abstract][Full Text] [Related]
2. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. Pickar D; Bartko JJ Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992 [TBL] [Abstract][Full Text] [Related]
5. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. Haas GL; Garratt LS; Sweeney JA J Psychiatr Res; 1998; 32(3-4):151-9. PubMed ID: 9793868 [TBL] [Abstract][Full Text] [Related]
6. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment]. Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y Encephale; 1991; 17(4):255-61. PubMed ID: 1683626 [TBL] [Abstract][Full Text] [Related]
7. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Kopala LC; Fredrikson D; Good KP; Honer WG Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777 [No Abstract] [Full Text] [Related]
8. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O; J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554 [TBL] [Abstract][Full Text] [Related]
9. Placebo washout in trials of antipsychotic drugs. Volavka J; Cooper TB; Laska EM; Meisner M Schizophr Bull; 1996; 22(4):567-76. PubMed ID: 8938911 [TBL] [Abstract][Full Text] [Related]
10. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. Finkelstein JR; Cannon TD; Gur RE; Gur RC; Moberg P J Abnorm Psychol; 1997 May; 106(2):203-12. PubMed ID: 9131840 [TBL] [Abstract][Full Text] [Related]
12. Symptomatic response to antipsychotics differs between recent onset and recurrent chronic schizophrenic patients. Hill C; Keks NA; Jackson H; Kulkarni J; Hannah D; Copolov D; Singh B Aust N Z J Psychiatry; 1992 Sep; 26(3):417-22. PubMed ID: 1358053 [TBL] [Abstract][Full Text] [Related]
13. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS]. Loas G; Noisette C; Legrand A; Delahousse J Encephale; 1997; 23(1):10-8. PubMed ID: 9172962 [TBL] [Abstract][Full Text] [Related]
14. RBC and plasma choline in neuroleptic-treated schizophrenic patients. Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429 [TBL] [Abstract][Full Text] [Related]
15. Zotepine in the treatment of acute hospitalized schizophrenic episodes. Kasper S; Quiner S; Barnas C; Fabisch H; Haushofer M; Sackel C; König P; Lingg A; Platz T; Rittmannsberger H; Stuppäck C; Willeit M; Zapotoczky HG Int Clin Psychopharmacol; 2001 May; 16(3):163-8. PubMed ID: 11354238 [TBL] [Abstract][Full Text] [Related]
16. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390 [TBL] [Abstract][Full Text] [Related]
17. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. Allan ER; Alpert M; Sison CE; Citrome L; Laury G; Berman I J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331 [TBL] [Abstract][Full Text] [Related]
18. Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. Albert N; Randers L; Allott K; Jensen HD; Melau M; Hjorthøj C; Nordentoft M Psychol Med; 2019 May; 49(7):1138-1147. PubMed ID: 30058511 [TBL] [Abstract][Full Text] [Related]
19. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis]. Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756 [TBL] [Abstract][Full Text] [Related]
20. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Wieselgren IM; Lindstrom LH Acta Psychiatr Scand; 1996 Jan; 93(1):9-19. PubMed ID: 8919324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]